Poly(D,L-Lactic-Co-Glycolic Acid) microsphere delivery of adenovirus for vaccination

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 2, 2007, Pages 215-228

  Wang, Daqing ^a   Molavi, Ommoleila ^a   Lutsiak, M E Christine ^a   Elamanchili, Praveen ^a   Kwon, Glen S ^a,b   Samuel, John ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; IODINE 125; MICROSPHERE; POLYGLACTIN; VIRUS ANTIBODY;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DISTRIBUTION; DRUG RELEASE; DRUG UPTAKE; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROVOCATION TEST; SPLEEN CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 34249341672     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Wilson, JM. Adenoviruses as gene-delivery vehicles. N Engl J Med, 334(18): 1185-7 1996.
2. Ghosh, SS., Gopinath, P., and Ramesh, A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol, 133(1): 9-29 2006.
3. Shiver, JW., and Emini, EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med, 55: 355-72 2004.
4. Tatsis, N., and Ertl, HC. Adenoviruses as vaccine vectors. Mol Ther, 10(4): 616-29 2004.
5. Barouch, DH., and Nabel, GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther, 16(2): 149-56 2005.
6. Lasaro, M., and Ertl, H. Human Papillomavirus-associated cervical cancer: prophyllactic and therapeutic vaccines. Gene Ther Mol Biol, 8(8): 291-306 2004.
7. Timares, L., Douglas, JT., Tillman, BW., Krasnykh, V., and Curiel, DT. Adenovirus-mediated gene delivery to dendritic cells. Methods Mol Biol, 246: 139-54 2004.
8. Xiang, ZQ., Yang, Y., Wilson, JM., and Ertl, HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology, 219(1): 220-7 1996.
9. Shiver, JW, et al. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature, 415(6869): 331-5 2002.
10. Lozier, JN, et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther, 13(1): 113-24 2002.
11. Schnell, MA, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther, 3(5 Pt 1): 708-22 2001.
12. Sumida, SM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol, 174(11): 7179-85 2005.
13. Sumida, SM, et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol, 78(6): 2666-73 2004.
14. Yang, Y., Li, Q., Ertl, HC., and Wilson, JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol, 69(4): 2004-15 1995.
15. Foged, C., Sundblad, A., and Hovgaard, L. Targeting vaccines to dendritic cells. Pharm Res, 19(3): 229-38 2002.
16. Song, W, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med, 186(8): 1247-56 1997.
17. Timares, L., Takashima, A., and Johnston, SA. Quantitative analysis of the immunopotency of genetically transfected dendritic cells. Proc Natl Acad Sci U S A, 95(22): 13147-52 1998.
18. Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol, 156(8): 2918-26 1996.
19. Brossart, P, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res, 58(4): 732-6 1998.
20. Nair, SK, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol, 16(4): 364-9 1998.
21. Waeckerle-Men, Y., and Groettrup, M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev, 57(3): 475-82 2005.
22. Elamanchili, P., Diwan, M., Cao, M., and Samuel, J. Characterization of poly(D,L-lacticco-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine, 22(19): 2406-12 2004.
23. Lutsiak, ME., Kwon, GS., and Samuel, J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol, 58(6): 739-47 2006.
24. Diwan, M., Elamanchili, P., Lane, H., Gainer, A., and Samuel, J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target, 11(8-10): 495-507 2003.
25. Newman, KD., Samuel, J., and Kwon, G. Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J Control Release, 54(1): 49-59 1998.
26. Rosas, JE, et al. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. Vaccine, 19(31): 4445-51 2001.
27. Jilek, S., Zurkaulen, H., Pavlovic, J., Merkle, HP., and Walter, E. Transfection of a mouse dendritic cell line by plasmid DNA-loaded PLGA microparticles in vitro. Eur J Pharm Biopharm, 58(3): 491-9 2004.
28. Hedley, ML., Curley, J., and Urban, R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med, 4(3): 365-8 1998.
29. Wang, D., Robinson, DR., Kwon, GS., and Samuel, J. Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release, 57(1): 9-18 1999.
30. Raychaudhuri, S., and Rock, KL. Fully mobilizing host defense: building better vaccines. Nat Biotechnol, 16(11): 1025-31 1998.
31. Wang, M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumorassociated antigen. J Immunol, 154(9): 4685-92 1995.
32. Graham, FL., Smiley, J., Russell, WC., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol, 36(1): 59-74 1977.
33. Ralph, P., and Nakoinz, I. Direct toxic effects of immunopotentiators on monocytic, myelomonocytic, and histiocytic or macrophage tumor cells in culture. Cancer Res, 37(2): 546-50 1977.
34. Miller, FR., Miller, BE., and Heppner, GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis, 3(1): 22-31 1983.
35. Bender, A., Sapp, M., Schuler, G., Steinman, RM., and Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods, 196(2): 121-35 1996.
36. Strunk, D, et al. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood, 87(4): 1292-302 1996.
37. Korbutt, GS., Smith, DK., Rajotte, RV., and Elliott, JF. Expression of beta-galactosidase in mouse pancreatic islets by adenoviral-mediated gene transfer. Transplant Proc, 27(6): 3414 1995.
38. Kanegae, Y., Makimura, M., and Saito, I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol, 47(3): 157-66 1994.
39. Precious, B., and Russell, WC, Growth, purification and titration of adenoviruses. In Virology: a practical approach. IRL, B.M. Mahy, Oxford, UK, 1985.
40. Everitt, E., Lutter, L., and Philipson, L. Structural proteins of adenoviruses. XII. Location and neighbor relationship among proteins of adenovirion type 2 as revealed by enzymatic iodination, immunoprecipitation and chemical cross-linking. Virology, 67(1): 197-208 1975.
41. Gavin, MA., Gilbert, MJ., Riddell, SR., Greenberg, PD., and Bevan, MJ. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol, 151(8): 3971-80 1993.
42. Oukka, M., Cohen-Tannoudji, M., Tanaka, Y., Babinet, C., and Kosmatopoulos, K. Medullary thymic epithelial cells induce tolerance to intracellular proteins. J Immunol, 156(3): 968-75 1996.
43. Merrifield, RB. Solid-phase protein synthesis: I. The synthesis of a tetrapeptide. J. Am. Chem. Soc, 85(85): 2149-2154 1963.
44. Ogawa, Y., Yamamoto, M., Okada, H., Yashiki, T., and Shimamoto, T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull (Tokyo), 36(3): 1095-103 1988.
45. Beer, SJ, et al. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther, 5(6): 740-6 1998.
46. Restifo, NP, et al. Identification of human cancers deficient in antigen processing. J Exp Med, 177(2): 265-72 1993.
47. Brubaker, JO, et al. Th1-associated immune responses to beta-galactosidase expressed by a replication-defective herpes simplex virus. J Immunol, 157(4): 1598-604 1996.
48. Chamberlain, RS, et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res, 56(12): 2832-6 1996.
49. Bronte, V, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol, 154(10): 5282-92 1995.
50. Davidson, BL., Hilfinger, JM., and Beer, SJ. Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors. Adv Drug Deliv Rev, 27(1): 59-66 1997.
51. Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, LH., and Langer, R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res, 8(6): 713-20 1991.
52. Bergstresser, PR., Fletcher, CR., and Streilein, JW. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J Invest Dermatol, 74(2): 77-80 1980.
53. Yang, Y., and Wilson, JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol, 155(5): 2564-70 1995.
54. Yang, Y., Jooss, KU., Su, Q., Ertl, HC., and Wilson, JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther, 3(2): 137-44 1996.
55. Garcia del Barrio, G., Hendry, J., Renedo, MJ., Irache, JM., and Novo, FJ. In vivo sustained release of adenoviral vectors from poly(D,L-lactic-co-glycolic) acid microparticles prepared by TROMS. J Control Release, 94(1): 229-35 2004.
56. Varshavsky, A. The N-end rule pathway of protein degradation. Genes Cells, 2(1): 13-28 1997.
57. Bachmair, A., Finley, D., and Varshavsky, A. In vivo half-life of a protein is a function of its amino-terminal residue. Science, 234(4773): 179-86 1986